Skip to search formSkip to main content

famitinib

An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundFamitinib is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2018
2018
AIM To establish and validate an ultra-high-performance liquid chromatography-tandem mass spectrometry method for the rapid and… Expand
Is this relevant?
2017
2017
AbstractBackgroundMetastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
513 Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and is the fifth leading cause of cancer… Expand
Is this relevant?
Review
2015
Review
2015
The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January 15-17) is the world-class conference co-sponsored by… Expand
  • table 1
Is this relevant?
2014
2014
AbstractPurpose Hypothyroidism is a common adverse event in patients treated with anti-VEGFR-2 targeting agents and may be a… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2013
2013
BACKGROUND AND PURPOSE Famitinib is a novel multi-targeted receptor tyrosine kinase inhibitor under development for cancer… Expand
Is this relevant?
2013
2013
AbstractPurpose To evaluate the safety, tolerability, pharmacokinetics and antitumor activities of famitinib (famitinib l-malate… Expand
  • table 2
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
2013
2013
BACKGROUND Famitinib is a novel and potent multitargeting receptor tyrosine kinase inhibitor. The phase I clinical study showed… Expand
Is this relevant?
2011
2011
Angiogenesis plays a key role in tumor progression and anti-angiogenic agents including sunitinib and sorafenib that target VEGF… Expand
Is this relevant?